

Research Agreement

THIS AGREEMENT is by and between Nestec Ltd., Avenue Nestlé 55, CH-1800 Vevey, Switzerland (hereinafter “Nestec”) and The University of Queensland, St. Lucia, QLD 4072 , Australia (hereinafter “University”).

WHEREAS, Nestec wants a research program conducted to compare metabolomic variables between normal cats and cats in diabetic remission (hereinafter “Research Program”); and

WHEREAS, University has available all equipment, facilities, and personnel necessary to conduct the Research Program and is willing to conduct such a Research Program for Nestec.

NOW, THEREFORE, in consideration of these premises and the mutual covenants contained herein, the parties hereto stipulate and agree as follows:

1. University agrees to:

1.1. Conduct the Research Program under the supervision of Dr. Jacquie Rand (hereinafter the “Principal Investigator”). The selection of any post-doctoral fellows, graduate students, technicians, and other persons to work on the Research Program shall be at the discretion of the Principal Investigator and University.

1.2. Provide all personnel, materials, facilities, equipment, labor, test animals, feed, and other requirements reasonably necessary to conduct the research and development program as defined in accordance with the Protocol entitled “Metabolomic Profiling of Cats At High Risk of Diabetes ,” attached hereto as Exhibit A and incorporated herein by reference. If there are any inconsistencies between the Protocol and this Agreement, the provisions of this Agreement shall prevail.

1.3. Perform all acts necessary to conduct the Research Program in accordance with the attached Protocol.

1.4. Disclose Confidential Information only on a need-to-know basis to those personnel within University’s organization who are obligated to maintain the secrecy of the Confidential Information and have been advised as to its confidential nature and of their obligation to maintain the secrecy of such Confidential Information.

1.5. Return to Nestec any uncommitted and unexpended funds paid to University if the Agreement is terminated pursuant to Section 3.4 herein.

1.6. Acknowledge Nestec’s concern with respect to the use of animals in research programs, treat all animals used in the Research Program in a humane manner and in accord with all federal, state and local guidelines, and use only qualified personnel for the handling, care and treatment of all animals used in the Research Program.

1.7. Comply with Nestec's Pet Care Ethical Policy (the "Policy"), attached hereto as Exhibit B and incorporated herein by reference, when conducting the Research Program or any other animal study related activity under the terms of this Agreement.

2. Nestec agrees to:

2.1. Compensate University for conducting the Research Program and performing any other obligations required hereunder an amount of Forty-four Thousand Six Hundred Thirty-five Australian Dollars (\$44,635) to be paid as follows:

Eighty-five percent (85%) within thirty (30) days after execution of this Agreement;
and

Fifteen percent (15%) to be due upon receipt of a complete Final Report.

3. Term and Termination

3.1. The Research Program shall be conducted during the period from July 2, 2012 to July 2, 2013.

3.2. The Research Program and this Agreement may be terminated by Nestec upon thirty (30) days' notice if in Nestec's opinion the validity of the Research Program is or may be impaired.

3.3. The provisions and obligations relating to confidentiality and limited use of information, inventions, data and results, and reports contained herein shall survive the expiration or termination of this Agreement.

3.4. The Research Program may be terminated by Nestec if the Principal Investigator becomes unable or unwilling to continue the Research Program and a mutually acceptable substitute is not available.

4. Funds and Equipment

4.1. The money paid by Nestec to University shall be expended for the Research Program as described in the attached Protocol for salaries, wages, fringe benefits, travel, equipment, supplies, clerical support, etc., as may be reasonably necessary to conduct the Research Program.

4.2. Funds received by University under this Research Agreement for purchasing equipment and supplies shall be applied so that title to all equipment and supplies purchased under this Research Agreement shall permanently vest in University.

5. Confidential Information

5.1. For University to perform its obligations under this Agreement, it may be necessary for Nestec to disclose to University certain information that Nestec considers to be highly confidential and proprietary. Nestec is willing to disclose this confidential and proprietary

information to University provided Nestec's rights are protected. Therefore, Nestec and University agree that:

5.1.1. "Confidential Information" for the purposes of this Agreement shall mean all information disclosed by Nestec to University relevant to this Agreement. Confidential Information includes, but is not limited to, Nestec's products and product plans, ongoing research and development efforts, and other information of a technical or economic nature related to Nestec's business.

5.1.2. Confidential Information will be used by University only for performing its obligations under this Agreement and that no Confidential Information will be, except as provided for herein, (1) disclosed to others, (2) published without the express written permission of Nestec, (3) used for University's or any others' benefit, or (4) duplicated in any manner; provided, however, that University's obligation of confidentiality and limited use shall not apply to Confidential Information that (a) is at the time of receipt by University public knowledge or after its receipt by University becomes public knowledge through no act or omission on the part of University, (b) was known to University as shown by University's written records before the disclosure thereof to University by Nestec, (c) is received by University from a third party who did not, directly or indirectly, obtain the Confidential Information from Nestec, or (d) was developed by the University independently of the Research under this Agreement.

5.1.3. Confidential Information will be returned to Nestec if requested.

5.2. University represents and warrants that each of its employees, associates, or other persons who have access to Confidential Information has entered into a written contract with University that prohibits the disclosure or use of Confidential Information in a manner inconsistent with the terms of this Agreement.

6. Intellectual Property

6.1. University and its employees and agents shall assign to Nestec all rights and interests to any and all inventions that are conceived or reduced to practice as a direct result of University's receipt and use of Confidential Information hereunder. However, any such inventions resulting from the receipt and use of the Confidential Information and intellectual property of the University existing prior to commencement of this Agreement shall vest in the parties jointly.

6.2. Except as set out in clause 6.1, University shall own all rights and interests to any and all inventions that are conceived or reduced to practice in the course of the Research Program.

6.3. Nestec shall not acquire any rights to any University intellectual property that existed as of the Effective Date.

6.4. University agrees to perform any acts and execute at Nestec's request, and at no expense to University, any and all papers and instruments that Nestec considers reasonably necessary to perfect and protect Nestec's rights, title and interest in and to inventions, discoveries, improvements and designs arising under clause 6.1.

6.5. University warrants that all persons working on the Research Program, as a condition of employment or otherwise, have agreed to assign to Nestec all inventions described in clause 6.1 made while working on the Research Program.

6.6. Each party may negotiate on arms-length commercial terms a license from the other party to any intellectual property rights, including patents, rights in relation to inventions, copyright, rights in relation to works or the Results or any other rights resulting of intellectual activity which arise from the conduct of the Research Program.

7. Materials, Data, and Results

7.1. It is understood and agreed that the materials, data, results, and other information generated or developed in the course of the Research Program (hereinafter "Results") shall be the property of Nestec when arising from use of the Nestec Confidential Information and otherwise shall be owned by University provided that each party may use those Results without prior approval of the other party for its internal use, for submission to regulatory agencies, for use in academic publications as set out in clause 8.

7.2. University agrees to deliver copies of the Results, including all original data, to Nestec as part of or along with the Final Report.

8. Publications

8.1. University shall have the right to publish the Results. Before submitting the Results for publication, however, University shall give Nestec an opportunity to review the proposed manuscript and will consider suggested modifications or reasonable delays to enable the filing of applications for patents or to remove any Nestec technical or other Confidential Information. If Nestec has provided University with Confidential Information, identified as such in writing, University agrees to remove any such Confidential Information upon request.

8.2. Nestec shall have sixty (60) days before submission for publication to review the proposed publication and either approve the publication in writing or suggest the above noted modifications or reasonable delays. In the event Nestec determines that patentable subject matter is contained in the proposed publication, University shall delay submission for publication for sixty (60) days to allow Nestec to file patent applications on the subject matter.

8.3. If University elects not to publish the Results, Nestec may, publish the Results. In such cases, University shall be given an opportunity to review the manuscript and it shall not be published until University has had sixty (60) days to review the manuscript and make suggested modifications, if any.

8.4. No publications shall be submitted for review before receipt of the Final Report.

8.5. If the Agreement is terminated pursuant to Section 3.4 herein, University shall not publish the Results without the express written permission of Nestec.

8.6. Publication by either party shall give proper credit to the other party for the cooperative character of this investigation, unless University or Nestec requests otherwise.

9. Reports

9.1. University agrees to keep accurate and complete records of the Results and to provide Nestec with a complete written report (“Final Report”) of the Results within thirty (30) days after (1) completion of the Research Program or (2) expiration or termination of this Agreement, whichever occurs first.

9.2. All rights in reports or other creative works arising from University’s receipt and use of the Nestec Confidential Information hereunder and the copyright therefore shall be owned by Nestec. Otherwise, such copyright shall vest in University.

10. Notices and Communications

10.1. All notices and other communications regarding this Agreement, including the reports called for herein, sent from University to Nestec shall be addressed to:

Nestlé Purina PetCare Global Resources, Inc.
Checkerboard Square
St. Louis MO 63164
Attention: Ziad Ramadan

10.2. All notices and other communications regarding this Agreement, including the payments called for herein, sent from Nestec to University shall be addressed to:

The University of Queensland
St. Lucia, QLD 4072
Australia
Attention: Jacquie Rand

10.3. All written notices required or permitted to be given under the terms of this Agreement shall be deemed duly delivered upon receipt if (1) delivered in person or (2) sent certified mail, return receipt requested to the above address. Notwithstanding the foregoing, payments, reports, and other routine communications may be sent by regular mail or electronic mail.

11. Miscellaneous Provisions

11.1. *Amendments in Writing.* This Agreement may be amended or modified only by a written instrument duly executed by an appropriate officer of each party.

11.2. *Assignments.* This Agreement shall be binding upon and inure to the benefit of the parties hereto, their respective successors and permitted assigns, provided that neither party hereto shall be able to assign any right, license, benefit, option, duty, obligation, or privilege hereunder without the prior consent of the other party, except in the event of the sale of all or substantially all of the business to which this Agreement relates by an assigning party. In the event of such assignment upon the sale of all or substantially all of the business to which this Agreement relates, due written notice of such assignment shall be provided to the other party.

11.3. *Future Relationships.* Other than as explicitly defined herein, nothing contained in this Agreement shall be construed, by implication or otherwise, as an obligation of any party hereto to enter into a further agreement regarding the subject matter of this Agreement. Further, nothing herein shall be construed to grant either party hereto a license, either express or implied, to any patent, know-how, trademark, or trade name of the other party.

11.4. *Headings.* The headings and titles to the articles and paragraphs in this Agreement are intended solely for convenience and shall be given no effect in the construction or interpretation of this Agreement.

11.5. *Implementation.* Each party shall, at the request of the other party, execute any document reasonably necessary to implement the provisions of this Agreement.

11.6. *Independent Contractors.* Nothing in this Agreement is intended or shall be deemed to constitute a partnership, agency, employer-employee or a joint venture relationship between the parties. The respective activities of the parties hereunder shall be provided as independent contractors. Neither party shall incur any debts or make any commitments for the other, except to the extent, if at all, specifically provided herein.

11.7. *Integration.* This written Agreement embodies the entire understanding between the parties and supersedes and replaces any and all prior negotiations, understandings, arrangements, and/or agreements, whether written or oral, relating to the subject matter hereof.

11.8. *Publicity.* Each party agrees not to use the name of the other party in any commercial activity, advertisement, sales brochures, or otherwise without written permission.

11.9. *Severability.* This Agreement is divisible and separable. If any provision of this Agreement is held to be or becomes invalid, illegal or unenforceable, such provision shall be reformed to approximate as nearly as possible the intent of the parties and shall remain valid and enforceable to the greatest extent permitted by law.

11.10. Waiver. The terms of this Agreement may be waived only by a written instrument expressly waiving such term or terms and executed by the party waiving compliance. The waiver of any term or condition of this Agreement by either party hereto shall not constitute a modification of this Agreement, nor prevent a party hereto from enforcing such term or condition in the future with respect to any subsequent event, nor shall it act as a waiver of any other right accruing to such party hereunder.

11.11. Warranty. Each party represents and warrants that it has the right to enter into this Agreement without breaching or violating any fiduciary, contractual, statutory, or other obligation owed to another.

IN WITNESS WHEREOF, the parties hereto caused this Agreement to be duly executed by their duly authorized representatives.

The University of Queensland

By: Excluded personal information 3 July 12
Ian G Harris
Title: Director, Research Partnerships
UQ Research and Innovation
The University of Queensland

Nestec Ltd.

By: Excluded personal information
Title: Director, Nestle Research Center

WRG/
Contract Number: 201200009
Distribution of Originals:
One (1) to Nestec Ltd.
One (1) to The University of Queensland

RTI RELEASE

Exhibit A

Protocol

Contract Number 201200009

Metabolomic Profiling of Cats At High Risk of Diabetes

Background:

Human type 2 diabetes is caused by a complex set of interactions between genetic and environmental factors. Recent work in humans has shown that type 2 diabetes comprises a constellation of disorders associated with a large number of genes and dysfunctions of multiple organ systems, including impaired insulin action in muscle and adipose tissues, defective control of hepatic glucose production and insulin deficiency caused by loss of β -cell mass and function¹. These complexities cause difficulties for understanding the molecular pathways that contribute to disease development, although insulin resistance is a known precursor of type 2 diabetes in humans.

In cats, diabetes mellitus is a relatively common endocrine disease, with 80 – 95% of feline diabetes analogous to human type 2 diabetes². The disease in cats is also characterised by inadequate insulin secretion and insulin resistance, and the incidence is increasing as the prevalence of feline obesity rises. Older, overweight cats are most at risk for developing diabetes and the Burmese breed in Australia and Europe have a four-fold increased risk compared with the general population³.

Diabetes in cats is usually diagnosed relatively late in the progression of disease, only after blood glucose levels exceed the renal threshold. Early diagnosis of diabetes in cats is difficult as the available diagnostic tests for insulin sensitivity (euglycemic clamp or frequently sampled intravenous glucose tolerance test) and glucose tolerance are time-consuming, expensive, require significant patient compliance and are usually not undertaken in clinical practice. Biological markers that predict which at-risk cats will progress to develop diabetes are not available. Cats in diabetic remission are at high risk of relapse and therefore represent an ideal group to study cats at risk of developing overt diabetes. Nestlé Purina has provided valuable support for collection of samples from cats in remission, and initial results have been presented as an ACVIM abstract in 2011.

Metabolomics is a rapidly evolving field that comprehensively measures endogenous metabolites, which are the net result of genomic, transcriptomic and proteomic variability, and therefore provide an integrated profile of biological status¹. In humans, such metabolic profiling has identified α -hydroxybutyrate as a significant metabolite associated with insulin sensitivity and an early marker for dysglycemia⁴. Given the established similarities between human type 2 diabetes and feline diabetes, it is hypothesised that similar metabolites in cats may be useful as markers for insulin resistance.

¹ Bain, J.R., Stevens, R.D., Wenner, B.R., Ilkayeva, O., Muoio, D.M. and Newgard, C.B. (2009) Metabolomics applied to diabetes research: moving from information to knowledge. *Diabetes* 58 (11) 2429-2443

² Rand, J. (1999). Current understanding of feline diabetes: part 1. Pathogenesis. *Journal of feline medicine and surgery* 1 (3), 143-153

³ Rand, J.S., et al. (1997). Over representation of Burmese cats with diabetes mellitus. *Australian Veterinary Journal* 75 (6) 402-405

⁴ Gall, W.E., Beebe, K., et al. (2010). α -hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a non-diabetic population. *PlosOne* 5 (5) e10883 (11 pages).

The proposed study therefore aims to determine metabolite profile differences between cats known to be at risk of diabetes (cats in diabetic remission) and healthy age-matched cats to better understand the metabolic characteristics of cats in remission and to develop an early diagnostic marker for cats at risk of feline diabetes.

Methodology:

In order to develop an early diagnostic screening test for feline diabetes, the proposed study aims to determine metabolite profile differences between healthy cats 8 years of age or older with normal glucose tolerance (n=20) and diabetic cats in remission(n=20) which are age, gender, body condition and breed matched. Cats in remission are at high risk of relapse with rates of relapse of 25-40%.

Funding is sought to perform metabolomic profiles on these cats at risk for diabetes and compare them with healthy age-matched cats. Data on glucose tolerance status is available for all cats in the study. Preliminary analysis of glucose concentrations at 3 and 4hrs after glucose injection has shown a clear differentiation between healthy cats and cats in remission, with the majority of cats in remission having glucose concentrations above 117 mg/dL (6.5 mmol/L) at 3 hours after 1g/kg glucose intravenously.

Samples have been collected for measurement of insulin, adiponectin, leptin and grehlin. Alpha hydroxybutyrate has been identified as a marker of insulin resistance in humans and measurement of insulin, leptin and adiponectin in this study would allow a preliminary comparison of alpha hydroxybutyrate concentrations with other measures of insulin sensitivity in cats such as fasting glucose:insulin ratios, and other simple measure of insulin sensitivity such as HOMA and Bennett's Index, and leptin:adiponectin ratio.

Samples will be processed by Metabolomics Australia and results analysed for significant correlations.

Exhibit B

Contract Number 201200009

Pet Care Ethical Policy

Nestec Ltd. and its affiliate Nestlé Purina PetCare Company (“Nestec”) are committed to making foods that dogs and cats enjoy while providing nutrition that enhances their health and well-being. We understand and share the strong feelings of love and respect pet owners develop for their companion animals. Therefore, at Nestec, the care of dogs and cats is a top priority.

Care of Animals at Pet Care Development Centers

Nestec maintains Pet Care Development Centers to better understand animal feeding behaviors and nutritional needs. These centers are designed to give the resident dogs and cats a comfortable and healthy environment. Each animal is given individual attention and treated with respect.

Research and Development involving cats and dogs

Nestec will only conduct tests on dogs and cats that are used in routine veterinary home care. We do not support or use any invasive procedures that cause cats and dogs to suffer. In addition, we do not participate in any research that requires inducing disease in or the euthanasia of dogs and cats.

Nestec's fundamental responsibility is to provide palatable and nutritious products made to the highest standards of quality and safety. Our efforts are guided by a code of ethics that meets or exceeds the standards of the relevant legislations.

Anthony Zgrajewski

From: Marlow,Tina,ST LOUIS,Intellectual Property Group
<Excluded personal information@purina.nestle.com>
Sent: Tuesday, 24 September 2013 6:41 AM
To: Science Contracts
Subject: RE: Variation to Research Agreement - UQ and Nestec
Attachments: 2013-08-16 St Louis - U of Queensland - Research Agr Amendment Signed.pdf

Dear Joanna,
Attached is the fully executed agreement. We do not require a hard copy.
Best regards,
Tina

From: Science Contracts [mailto:sciencecontracts@uq.edu.au]
Sent: Sunday, September 15, 2013 11:51 PM
To: Marlow,Tina,ST LOUIS,Intellectual Property Group
Subject: FW: Variation to Research Agreement - UQ and Nestec

Dear Tina

Further to the email below, our records show that we have yet to receive a response from your office. Could you please provide a fully executed copy of the **attached** agreement. If you require an original copy of this agreement, could you please inform us of such and we will arrange to have the hard copies posted to the following address:

Nestle Purina Petcare Global Resources, Inc.
Checkerboard Square, 1C
St. Louis, Missouri 63164

We look forward to your response.

Kind regards

Joanna Lane, Contracts and Commercialisation Intern
Science Contracts
Faculty of Science
Level 3, Building 69, St Lucia
The University of Queensland 4072
P: +61 7 336 57020 E: sciencecontracts@uq.edu.au W: www.uq.edu.au/science

From: Science Contracts
Sent: Friday, 26 July 2013 11:07 AM
To: <Excluded personal information@purina.nestle.com>
Subject: Variation to Research Agreement - UQ and Nestec

Dear Tina,

Attached is a signed copy of the Variation to the Research Agreement for Jacquie Rand. If an electronic copy is sufficient for Nestec's contract requirements, please return a fully executed copy. Alternatively, Science Contracts will arrange for the originals to be sent to Nestec.

Kind regards,

Bryton Chin, Contracts and Commercialisation Intern
Faculty of Science
Level 3, Building 69, St Lucia
The University of Queensland 4072
E: sciencecontracts@uq.edu.au W: www.uq.edu.au/science
T: +61 7 336 57020

RTI RELEASE

RESEARCH AGREEMENT AMENDMENT

THIS AGREEMENT is by and between Nestec Ltd., Avenue Nestlé 55, CH-1800 Vevey, Switzerland (hereinafter "Nestec") and The University of Queensland, St. Lucia, QLD 4072, Australia (hereinafter "University").

WHEREAS, under the terms of Agreement No. 201200009 University was to have conducted a program of research to compare metabolomic variables between normal cats and cats in diabetic remission (hereinafter "Research"); and

WHEREAS, the term of said Agreement was from July 2, 2012 to July 2, 2013; and

WHEREAS, the parties have concluded that additional time is needed for University to conduct the Research, and the parties have mutually agreed to extend such period.

NOW, THEREFORE, in consideration of these premises and the mutual covenants herein, the parties agree as follows:

The term defined in Paragraph 3.1 is extended through December 31, 2013.

All other terms and conditions remain as defined in the Agreement.

IN WITNESS WHEREOF, the parties hereto caused this Agreement to be duly executed by their duly authorized representatives.

The University of Queensland

Nestec Ltd.

Excluded personal information

Excluded personal information

By: _____

By: _____

Title: _____

Title: HEAD OF IN-LICENSING AND R&D ALLIANCES

Date: 23 July 13

Date: 16.08.2013

Ian G Harris
Director, Research Partnerships
UQ Research and Innovation
The University of Queensland

From: Centre for Companion Animal Health
Sent: Thursday, 7 February 2013 4:07 PM
To: Excluded personal information @rd.nestle.com
Cc: Jacquie Rand Excluded personal information @rd.nestle.com
Subject: FW: 013747 RM2012000769 - Invoice 3190010861
Attachments: 3190010861.pdf

Importance: High

Follow Up Flag: Follow up
Flag Status: Flagged

Hi Denise,


Professor Jacquie Rand and Dr Ziad Ramadan have asked that I follow up on the first invoice relating to Nestle' grant with The University of Queensland. Please find attached our original invoice forwarded on the 6 September, 2012.

If any of the details our incorrect on this invoice, please notify me immediately, so that we can correct our records.

Kind regards,

Michele

Michele Rice
Personal Assistant to Prof. Jacquie Rand
Centre Research Co-ordinator - Centre for Companion Animal Health
School of Veterinary Science
The University of Queensland 4072
Ph: +61 7 3365 2122
Fax: +61 7 3346 9822
www.uq.edu.au/ccah
CRICOS Provider Number 00025B



From: Dain Heffernan
Sent: Thursday, 7 February 2013 3:29 PM
To: Centre for Companion Animal Health
Subject: FW: 013747 RM2012000769 - Invoice 3190010861

Dain Heffernan
Senior Finance Officer
School of Veterinary Science
T: 61 7 5460 1984 (internal ext. 50984)

From: Fbs Cga Science
Sent: Thursday, 7 February 2013 3:14 PM
To: Dain Heffernan
Subject: RE: 013747 RM2012000769 - Invoice 3190010861

Hi Dain,

Please see attached.

Thanks.

Kind regards,

Chanchala Adhikary

Accountant, Contract & Grants Accounting Section

Finance & Business Services Division | The University of Queensland | QLD 4072 | Australia

t. 07 3365 2885 | f. 07 3365 1511 | e. c.adhikary@uq.edu.au | w. www.fbs.uq.edu.au/contract-and-grants



From: Dain Heffernan
Sent: Thursday, 7 February 2013 2:48 PM
To: Fbs Cga Science
Cc: Centre for Companion Animal Health
Subject: RE: 013747 RM2012000769 - Invoice 3190010861

Yes – that would be great!

Thanks,

Dain Heffernan

Senior Finance Officer

School of Veterinary Science

T: 61 7 5460 1984 (internal ext. 50984)

From: Fbs Cga Science
Sent: Thursday, 7 February 2013 2:16 PM
To: Dain Heffernan
Subject: FW: 013747 RM2012000769 - Invoice 3190010861

Hi Dain,

It is still outstanding, please see the below AR screen shot. Do you need an invoice copy?

RTI RELEASE

Unit: UQ001 **Customer:** 100006789 Nestle Purina PetCare Global Res, Inc
Item ID: 3190010861 **Line:** **Days Late:** 124 **Status:** Open

Balance: 37,939.75 AUD

Item Activities				Find V
Sequence:	1	Accounting Date:	06/09/2012	Posted Date: 06/09/2012
Entry Type	IN	Reason:	REG	Voucher ID:
Document:				Amount:
Group Unit:	UQ001	Group ID:	60617	Billing

Kind regards,

Chanchala Adhikary

Accountant, Contract & Grants Accounting Section
 Finance & Business Services Division | The University of Queensland | QLD 4072 | Australia
 t. 07 3365 2885 | f. 07 3365 1511 | e. c.adhikary@uq.edu.au | w. www.fbs.uq.edu.au/contract-and-grants



From: Dain Heffernan
Sent: Thursday, 7 February 2013 1:45 PM
To: Fbs Cga Science
Subject: 013747 RM2012000769

Hi Chanchala,

Are you able to check if the first invoice for this project was outstanding? The granting body has sent CCAH an email checking if it's been paid. Also – the final report has been submitted but not accepted yet. The agreement wasn't clear on payment of the final invoice but if it was due on submission and acceptance of final report it may be coming soon.

Thanks as always,

Dain Heffernan
 Senior Finance Officer
 School of Veterinary Science
 The University of Queensland | Gatton, QLD 4343
 T: 61 7 5460 1984 (ext. 50984)
 F: 61 7 5460 1922
 email d.heffernan1@uq.edu.au | web www.uq.edu.au

This email is intended solely for the addressee. It may contain private or confidential information. If you are not the intended addressee, you must take no action based on it, nor show a copy to anyone. Kindly notify the sender by reply email. Opinions and information in this email which do not relate to the official business of The University of Queensland shall be understood as neither given nor endorsed by the University.

TAX INVOICE



Invoice Number: 3190010861
Invoice Date: 06 Sep 2012
Payment Terms: Net 30
Due date: 06 Oct 2012
Page: 1 of 1

Customer Number: 100006789
Customer Name: Nestle Purina PetCare Global Res, Inc
For Attention of: Finance Contact
 Checkerboard Square
 St Louis MO 63164
 United States

Customer Order #: 201200009
UQ Provider:

For Billing enquiries, please contact Contract and Grants Accounting section on +61 7 3365 2442 or email: research.science@uq.edu.au

Line	Description	Qty	UoM	Unit Amt	Net Amt	GST	Total
1	Research project UQ Project: 013747	0.00		0.00	37,939.75	0.00	37,939.75

Milestone 1: execution of this Agreement

PO: 4520348541

Amount Due: AUD 37,939.75

Your reference: 201200009

Award title: Metabolomic profiling of cats at high risk of diabetes

Chief Investigator: Jacqueline Rand

REMITTANCE ADVICE

Payment Amount: AUD 37,939.75



Bill Code: Excluded financial information
Reference: Excluded financial information

Telephone & Internet Banking – BPAY®

Contact your bank or financial institution to make this payment from your cheque, debit, credit or transaction account. More info: www.bpay.com.au.

*Registered to BPAY Pty Ltd ABN 69 079 137 518

Electronic Funds Transfer: - A Remittance Advice must be forwarded to the email address or fax number below.

Financial Institution:	Aus & NZ Banking Group Ltd	Branch Address:	Staff House Road
Title of Account:	Uni of Qld No1 Account		Uni of Qld
Financial Institution Code (BSB):	Excluded financial information		St Lucia, QLD, 4072
Account Number:	Excluded financial information	Remittance Email Address:	cash@uq.edu.au
Swift Code:	Excluded financial information	Remittance Fax Number:	+61 7 3365 1511

Cheque Payments: - Please quote invoice number when making payment.

Please make cheques payable to: The University of Queensland
 Send to: Accounts Receivable
 St Lucia, Qld, 4072 Australia

Credit Card: - If paying by credit card, please ensure this remittance advice is only submitted via fax#: +61 7 3365 1511

MasterCard Visa American Express

Card Number: _____ Expiry Date: ____/____/____

Cardholder Name: _____ Signature: _____